Keynote Speaker
Gerald Meyer, MBA, PharmD, FASHP, ASHP President-Elect
Director of Experiential Education, Jefferson School of Pharmacy, Thomas Jefferson University, Philadelphia, PA
Educational Objectives: Pending
Preparing for Biosimilars: Balancing the Promise with the Reality of Practice
Steven Lucio, PharmD, BCPS
Director, Pharmacy Clinical Solutions, Novation
Educational Objectives
- Explain critical principles that govern the manufacture of biologics, including biosimilars;
- Summarize key elements of the US biosimilar approval pathway;
- Describe the differences in the marketing of biosimilars as compared to generic small molecules;
- Differentiate true safety and efficacy considerations of biosimilars from commonly referenced misperceptions.
Are Your Purchasing Practices Safe?
Tips to Keep Counterfeit, Stolen, Tainted and Diverted Drugs from Entering Your Supply Chain
William H. Woodward, MS, RPh
Senior Director Sourcing Operations, Novation LLC
Educational Objectives
- Develop a plan to prepare their organizations for the introduction of this new product category;
- Participants will be able to describe weaknesses in current drug acquisition and distribution practices;
- Participants will be able to describe the weaknesses in current pedigree laws and regulations;
- Participants will be able to describe steps they can take at their own institutions to reduce the likelihood of acquiring tainted, stolen, or counterfeit pharmaceutical products.
Immune Globulin Intravenous: Product Evaluation and Formulary Considerations
Eric M. Tichy, PharmD, BCPS
Senior Clinical Pharmacy Specialist; Solid Organ Transplant and Director, PGY-2 Residency – Transplant, Yale-New Haven Hospital
Educational Objectives
- Review the clinically relevant differences between Immune Globulin Intravenous (IGIV) products;
- Describe operational considerations when converting between IVIG products;
- Compare and contrast the common adverse events associated with different IGIV projects and strategies for mitigating these events;
- Explain the role of the pharmacist in choosing an ideal IGIV agent for hospital or health-system formulary.
Essential Guidelines for Hospital Pharmacists in Acute Coronary Syndrome
Paul P. Dobesh, Pharm.D., FCCP, BCPS (AQ Cardiology)
Associate Professor of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE
Educational Objectives: Pending
A sixth CE program is in development and will be announced shortly.
NEW
New Practitioners Leadership Development Program
Special track for Residents and PharmD students Special Breakout Session for Pharmacy Residents
More to be announced!